We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Carador Eur | LSE:CIF | London | Ordinary Share | IE00B10RXS64 | ORD NPV (EUR) |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.6775 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 0.6775 | EUR |
Carador Eur (CIF) Share Charts1 Year Carador Eur Chart |
|
1 Month Carador Eur Chart |
Intraday Carador Eur Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 29/10/2012 | 12:01 | CARADOR INCOME FUND :::::::::::::::: Distressed loans | 124 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 29/10/2012 11:58 by jonwig Solarno - discussion is more active on the other thread (see CIFU), since the original 'CIF' - the shares - has expired.Edison cover both CIFU as well as GLIF. In simplistic terms, CIFU is further along the road in inoculating its CLO portfolio from market risk by transfer of income to preserve capital. In a severe market upset, though, I have no idea which of the two would take the bigger hit - GLIF is leveraged at company level, but CIFU at CLO level. |
Posted at 29/10/2012 11:47 by solarno lopez In view of Greenwich (GLIF) results today and increased dividend with a yield of 10.4% does anybody have any up to date comments on CIF yielding over 14% please |
Posted at 23/8/2012 16:35 by dendria Comment from Dexion just posted on the Carador News page:Dexion Capital, 22nd August 2012, "Dexion Daily Digest, Carador Income - July NAV" Dexion comment: "The strong performance in July of the ordinary share NAV (+4.8% NAV total return) again showed the benefit of receiving income. The first two months of a calendar quarter (with a bias to the first month) have historically shown to have the strong cash-flow receipts for the portfolio. As the pricing of the CLO assets does not fully adjust for the cash-flow, the NAV performs strongly. The strong performance takes the NAV total return for this year to 24.4%, an impressive return. With the strong NAV for July, the premium on the ordinary shares was 3.3%, similar to the C shares despite the latter not being fully invested and the ordinary share portfolio likely to have benefitted from further cash-flow during August. The ordinary shares therefore look better value and with defaults remaining low (the trailing 12 month default rate on US senior loans was 1.0% at the end of July and was 2.0% for US high yield bonds), return prospects remain strong in the short-term, although defaults are expected to increase in the medium term.". |
Posted at 06/8/2012 18:41 by dendria Quite a significant one-day rise. I hope we're not going to take off quite yet as I'm not fully invested - that's despite CIFU being my largest holding by far. I expect that now CIFU is effectively a $500M+ company it will start to appear on the radar of a number of new institutionals and indices after the latest C share issue is converted. |
Posted at 20/6/2012 12:53 by dendria Today's RNS (Wed 20/06/12) confirms new C Shares to take further advantage of the CLO market.'...the Directors have determined to issue new C shares of up to approximately $125 million, through a placing which is expected to close towards the end of July 2012.' I assume we don't get the RNS in the heading anymore as we stayed with CIF (as opposed to CIFU)? |
Posted at 26/5/2012 09:11 by jonwig CIF won't exist after 29 May, it will be CIFU alone, following the compulsory conversion.I can start a new thread, or stick with this one, simply removing the old CIF chart and living with the smaller CIFU charts. I'd prefer the latter, as it makes it easier to refer back through the posts for anyone who wants to. |
Posted at 09/5/2012 07:47 by jonwig Edison are doing a good job of presenting the company to investors (for which they charge!) but it doesn't seem to be having much impact on the share price.We're told the portfolio of CLOs is getting less risky , which I believe, so a yield to redemption of around 15% or more seems a massive undervaluation. What would be a fair valuation? 10%? That suggests a share price of at least $1.13. (Assuming static NAV and divi, and wind-up in 2019.) |
Posted at 17/3/2012 10:20 by dendria From IMS on 8 Nov 11 here are 'the year to date' figures:USD Share Class (CIFU) Share Price 81.75c NAV per Share 79.25c Premium = 3.15% Total Return = 19.73% EUR Share Class (CIF) Share Price 64.50c NAV per Share 60.24c Premium = 7.07% Total Return = 25.66% I hold CIFU simply as they are much more widely traded (as jonwig states above). |
Posted at 17/3/2012 09:20 by dendria alettsIreland-registered with full LSE listing so the shares are ISAable with no stamp duty. CIF = Euro type CIFU = USD type CIFC = USD 'C' type Some brokers do not trade it so you have to shop around brokers that do trade it usually offer the USD type (CIFU). My CIFU are with IWeb. I added Friday morning. |
Posted at 16/3/2012 11:56 by jonwig Broker comment from Dexion. Copied from i i:CIFU* - Carador Income Fund - February NAV and dividend Invests in a diversified portfolio of bank loans through CLO structures The NAV as at 29 February 2012 was USD 0.8761 per USD share (up 6.59% during the month), EUR 0.6682 per EUR share (up 6.44%), and USD 1.0227 per C share (up 2.38%). The NAV increases were net of an accrued performance fee. Distributions received from the income notes for the general portfolio (excluding C shares) were USD 15.99m, up 15.45% versus the fourth quarter to the end of November 2011, while the income from the mezzanine and senior investments was USD 1.26m, down 1.74% over the same period. Net income was USD 11.93m, up 18.06% with respect to the fourth quarter. For the C share portfolio, USD 0.85m of net income was generated. The C share portfolio was 61% invested at the end of January 2012 and 88% invested at the end of February 2012. During March, the C share portfolio has acquired 5 further investments; excluding the Q1 2012 dividend, the pro-forma cash for the C share portfolio was USD 6.7m as at 14 March 2012. The company declared a dividend of USD 0.033 per USD share, EUR 0.025 per EUR share and USD 0.01 per USD C share for the period 1 January 2012 to 31 March 2012, with an ex-dividend date of 21 March 2012, payable on 26 April 2012. Dexion comment This was a stunning NAV from the company, representing the best monthly performance since January 2011 and building on the impressive 5.4% return in January 2012. The USD ordinary share NAV return is now 12.4% for the year. The CLO market has rebounded this year, with investors returning to a space where the potential returns look substantially more attractive in an improving economic environment. In addition to the general positive market pricing trend, the ordinary share portfolio benefitted from evidence of an increased number of transactions, resulting in a narrower range of quotes for positions (the company's assets are valued at an average bid price), and marks not fully reflecting the distribution of income. The C share portfolio, while having a strong month, did not benefit to the same extent given the positions were recently acquired (and therefore pricing is more accurate) and received less in terms of income distribution during the month. Furthermore, the C share portfolio was not fully invested during the month. The C shares will convert into ordinary shares based on the respective February NAVs, less the declared dividends. This implies an eventual conversion ratio of 1.201 ordinary shares per C share, although both are currently trading cum-dividend, so the ratio is 1.167 until the ex-dividend date of 21 March 2012. The ordinary shares are currently trading on a c. 3.7% premium to the February NAV (share price of USD 0.9087), while the C shares trade on a 4.6% premium (share price of USD 1.07). We see scope for further capital appreciation, although income is likely to be a stronger driver of returns. The dividend of USD 0.033 per ordinary share represents a very attractive yield of 14.5% (based on a share price of USD 0.9087). |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
